[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Elazığ Mental Health and Diseases Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":213},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,72,102,124,142,168,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645203","type-d-personality-and-life-satisfaction-in-bipolar-disorder-type-2-and-major-depressive-disorder-100645203",false,"NCT07679204","Type D Personality and Life Satisfaction in Bipolar Disorder Type 2 and Major Depressive Disorder","Examination of Type D Personality and Factors Associated With Life Satisfaction in Parents of Patients Diagnosed With Bipolar Disorder Type 2 and Major Depressive Disorder","1. For Bipolar Disorder Type II (BD-II) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of BD-II according to DSM-5-TR\n   * Remission period\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Bipolar Disorder Type II (BD-II) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than BD-II and not in remission for BD-II\n   * Alcohol\u002Fdrug\u002Fsubstance use\n2. For Major Depressive Disorder (MDD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MDD according to DSM-5-TR\n   * Remission period\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Major Depressive Disorder (MDD) Group:\n   * Exclusion Criteria:\n\n     * Hypertension\n     * Diabetes mellitus\n     * Chronic kidney disease\n     * Rheumatoid arthritis\n     * Systemic lupus erythematosus\n     * Cardiac illness\n     * Severe neurological disorders\n     * Immunological or systemic illness\n     * Primary psychiatric disorders other than MDD and not in remission for MDD\n     * Alcohol\u002Fdrug\u002Fsubstance use\n3. For Healthy Control (HC) Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Healthy Control (HC) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Having psychiatric disorders\n   * Alcohol\u002Fdrug\u002Fsubstance use\n4. For Healthy Father and\u002For Mother of Bipolar Disorder Type II (BD-II) Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Healthy Father and\u002For Mother of Bipolar Disorder Type II (BD-II) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Having psychiatric disorders\n   * Alcohol\u002Fdrug\u002Fsubstance use\n5. For Healthy Father and\u002For Mother of Major Depressive Disorder (MDD) Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Healthy Father and\u002For Mother of Major Depressive Disorder (MDD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n\n   • Severe neurological disorders\n   * Immunological or systemic illness\n   * Having psychiatric disorders\n   * Alcohol\u002Fdrug\u002Fsubstance use\n6. For Healthy Father and\u002For Mother of Healthy Control (HC) Group:\n\n   \\*Inclusion Criteria:\n\n   • No psychiatric diagnosis\n\n   • No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years\n   * Provided informed consent\n\n   For Healthy Father and\u002For Mother of Healthy Control (HC) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Having psychiatric disorders\n   * Alcohol\u002Fdrug\u002Fsubstance use",true,"ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","OBSERVATIONAL","Bipolar Disorder Type II (BD-II) and Major Depressive Disorder (MDD) are common mood disorders associated with substantial psychological distress, impaired functioning, and reduced quality of life. BD-II is characterized by recurrent major depressive episodes and hypomanic episodes, whereas MDD is characterized by one or more major depressive episodes without a history of mania or hypomania. Both disorders have a significant genetic component, and family studies suggest that first-degree relatives may exhibit subclinical affective traits, personality characteristics, and psychosocial vulnerabilities related to these conditions. The aim of this cross-sectional study was to examine Type D personality traits and life satisfaction among patients with BD-II and MDD and parents of patients. The study recruited\u002Fwill recruit 30 patients with BD-II; 30 patients with MDD; 30 healthy control subjects; mothers and\u002For fathers of 30 healthy control subjects, mothers and\u002For fathers of 30 patients with BD-II, and mothers and\u002For fathers of 30 patients with MDD who are in remission and receiving follow-up care at the Psychiatry Outpatient Clinic of Elazığ Fethi Sekin City Hospital, Turkey (By Dilek ÖRÜM -Associate Professor of Psychiatry, dr.dilekulukan@gmail.com). Sociodemographic characteristics, Type D personality traits, general psychiatric symptoms, and life satisfaction assessed\u002Fwill be assessed using validated self-report measures, including the Type D Personality Scale (DS14), the Brief Psychiatric Rating Scale (BPRS), and the Adult Life Satisfaction Scale (ALSS).\n\nThe primary objective was\u002Fis to compare Type D personality characteristics and life satisfaction levels between patients with MDD and BD-II and between their parents. Secondary objectives included\u002Finclude investigating the associations between Type D personality traits, psychiatric symptom severity, and life satisfaction. The findings may contribute to a better understanding of familial psychological characteristics associated with mood disorders and may help identify potential psychosocial targets for preventive and supportive interventions among family members of affected individuals.",[25,26],"Bipolar Disorder II","Major Depressive Disorder (MDD)",[28,29,30,31],"Bipolar disorder type II","Major depressive disorder","Life satisfaction","Type D personality","RECRUITING","2026-06-25",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2024-12-23",{"date":40,"type":21},"2026-12-24",{"name":42,"class":43},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":71,"locationsCount":44},"100627683","cognitive-disengagement-syndrome-in-functional-neurological-symptom-disorder-100627683","NCT07451821","Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder","Symptoms of Sluggish Cognitive Tempo\u002FCognitive Disengagement Syndrome in Functional Neurological Symptom Disorder\u002FConversion Disorder: A Cross-Sectional Case-Control Study","* Inclusion Criteria for the Functional Neurological Symptom Disorder (FNSD) Group:\n\n  1. Meeting the diagnostic criteria for FNSD\u002FCD according to DSM-5-TR at the time of admission\n  2. Being between 18-65 years of age\n  3. Absence of additional psychiatric disorders\n  4. Absence of alcohol\u002Fsubstance use disorder\n  5. Absence of neurological disorders affecting cognition\n  6. Being in remission with FNSD\u002FCD\n  7. Completing sociodemographic data fully\n  8. Willingness to complete the forms and scales.\n  9. Willingness to participate in the study\n* Exclusion Criteria for the FNSD Group:\n\n  1. Being under 18 or over 65 years of age\n  2. Not meeting the diagnostic criteria for FNSD\u002FCD according to DSM-5-TR\n  3. Active alcohol\u002Fsubstance use\n  4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)\n  5. Not being willing to participate in the study\n  6. Incomplete sociodemographic data\n  7. Not being willing to complete forms and scales.\n* Inclusion Criteria for the Healthy Control (HC) Group\n\n  1. Being between 18-65 years of age\n  2. Not having any psychiatric disorder\n  3. Not having an alcohol\u002Fsubstance use disorder\n  4. Not having a neurological disorder affecting cognition\n  5. Completing sociodemographic data in full\n  6. Being willing to complete the forms and scales.\n  7. Being willing to participate in the study\n* Exclusion Criteria for the HC Group:\n\n  1. Being under 18 or over 65 years of age\n  2. Having a psychiatric disorder\n  3. Active alcohol\u002Fsubstance use\n  4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)\n  5. Not being willing to participate in the study\n  6. Incomplete sociodemographic data\n  7. Not being willing to complete forms and scales.","65 Years",{"count":54,"type":21},100,"This cross-sectional observational case-control study aims to investigate symptoms of sluggish cognitive tempo (SCT), also known as cognitive disengagement syndrome (CDS), in adults diagnosed with Functional Neurological Symptom Disorder\u002FConversion Disorder (FNSD\u002FCD). The study compares SCT\u002FCDS symptoms between patients with FNSD\u002FCD and healthy controls and evaluates their relationship with clinical variables. It is hypothesized that individuals diagnosed with FNSD\u002FCD will exhibit higher levels of SCT\u002FCDS symptoms compared to healthy controls.",[57],"Functional Neurological Symptom Disorder",[59,60,61,57,62,63,64],"Sluggish Cognitive Tempo","Cognitive Disengagement Syndrome","Conversion Disorder","Dissociation","Attention","Daydreaming","NOT_YET_RECRUITING","2026-06-24",{"date":68,"type":36},"2026-06-29",{"date":35,"type":21},{"date":40,"type":21},{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":52,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100628256","psychiatric-symptom-characteristics-in-methamphetamine-induced-psychosis-with-and-without-lifetime-cannabis-use-100628256","NCT07459270","Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use","Investigation of Factors Associated With Psychiatric Symptoms in Participants Diagnosed With Methamphetamine-Induced Psychotic Disorder With and Without Lifetime Cannabis Use","1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n   * Diagnosis of Cannabis Use Disorder according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n\n   • Medication-free for at least one month prior to admission\n\n   • Age ≥ 18 years and \\\u003C65 years\n\n   • Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder","MALE",{"count":81,"type":21},90,"This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included.\n\nParticipants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments.\n\nThe study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.",[84,85],"Methamphetamine Induced Psychosis","Cannabis Use",[87,88,89,90,91,92,93],"Methamphetamine","Cannabis","Marijuana","Psychiatric Symptoms","Longitudinal Study","Methamphetamine-Induced Psychotic Disorder","Lifetime Cannabis Use","2026-03-04",{"date":96,"type":36},"2026-03-09",{"date":98,"type":21},"2026-03-16",{"date":100,"type":21},"2026-11-23",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":52,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100628254","ecg-findings-in-methamphetamine-use-100628254","NCT07459244","ECG Findings in Methamphetamine Use","Electrocardiogram Findings in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Prospective Observational Cohort Study","1. For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MUD according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MUD\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MP according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n3. For Healthy Control Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Healthy Control Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than schizophrenia\n   * Alcohol\u002Fdrug\u002Fsubstance use",{"count":110,"type":21},240,"This prospective cohort study aims to examine and compare electrocardiogram (ECG) parameters in subjects diagnosed with Methamphetamine Use Disorder (MUD) and Methamphetamine-Induced Psychotic Disorder (MP) during inpatient psychiatric treatment. ECG findings at hospital admission and during remission prior to discharge will be evaluated and compared between groups. The study also aims to determine whether methamphetamine-induced psychosis is associated with greater ECG abnormalities and increased cardiac risk compared to methamphetamine use without psychosis.",[113,84],"Methamphetamine Use Disorder",[87,113,115,116,117],"Methamphetamine-Induced Psychosis","Electrocardiography","Cardiac Risk",{"date":96,"type":36},{"date":120,"type":36},"2025-04-07",{"date":122,"type":21},"2026-05-11",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":52,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":44},"100628255","psychiatric-symptom-predictors-in-methamphetamine-induced-psychosis-100628255","NCT07459257","Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis","Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study","* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  \\*Inclusion Criteria:\n  * Diagnosis of MP according to DSM-5-TR\n  * Medication-free for at least one month prior to admission\n  * Age ≥ 18 years and \\\u003C65 years\n  * Provided informed consent\n* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  * Exclusion Criteria:\n\n    * Hypertension\n    * Diabetes mellitus\n    * Chronic kidney disease\n    * Rheumatoid arthritis\n    * Systemic lupus erythematosus\n    * Cardiac illness\n    * Severe neurological disorders\n    * Immunological or systemic illness\n    * Primary psychiatric disorders other than MP\n    * Alcohol use disorder",{"count":132,"type":21},150,"This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed\u002Fwill be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed\u002Fwill be assessed monthly using standardized psychometric instruments.\n\nThe study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.",[84],[87,115,90,92,91],{"date":96,"type":36},{"date":138,"type":36},"2025-02-03",{"date":140,"type":21},"2026-08-17",{"name":42,"class":43},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":44},"100627149","il-33-sst2-and-crp-in-panic-disorder-100627149","NCT07444879","IL-33, sST2, and CRP in Panic Disorder","Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study","1. For Panic Disorder (PD) Group:\n\n   \\*Inclusion Criteria:\n   * Being between 18-65 years of age\n   * Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder\n   * Not having previously used any medication for psychiatric purposes (drug-naive)\n   * Not having any additional active psychiatric disorders besides PD at the current presentation\n   * Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n   * Not having taken any medication or supplements in the last month\n   * Completing sociodemographic and scale data fully\n   * Volunteering to participate in the study\n\n   For PD Group:\n\n   \\*Exclusion Criteria:\n\n   • Being outside the 18-65 age range\n\n   • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health\n\n   • Having a history of psychiatric medication use\n\n   • Having an additional psychiatric disorder besides PD at the current application\n\n   • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer\n\n   • Patients with a body mass index (BMI) \\\u003C18.5 kg\u002Fm² and \\>29.9 kg\u002Fm²\n   * Taking any medication or supplement in the last month\n   * Incomplete completion of sociodemographic and scale data\n   * Not volunteering to participate in the study\n2. For Healthy Control Group:\n\n   * Inclusion Criteria:\n\n     * Being between 18-65 years of age\n     * Not having any active psychiatric disorder\n     * Not having previously used any medication for psychiatric purposes (drug-naive)\n     * Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n     * Not having taken any medication or supplement in the last month\n     * Completing sociodemographic and scale data fully\n     * Volunteering to participate in the study\n\nFor Healthy Control Group:\n\n\\*Exclusion Criteria:\n\n* Being outside the 18-65 age range\n* Having any active psychiatric disorder\n* Having a history of using psychiatric medication\n* Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n* Patients with a body mass index (BMI) \\\u003C 18.5 kg\u002Fm² and \\> 29.9 kg\u002Fm²\n* Taking any medication or supplement in the last month\n* Incomplete completion of sociodemographic and scale data\n* Not volunteering to participate in the study",{"count":150,"type":21},80,"Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33\u002FsST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.",[153],"Panic Disorder",[153,155,156,157,158,159,160],"Interleukin-33","IL-33","Soluble Suppressor Tumorogenicity-2","sST2","CRP","C-Reactive Protein","2026-03-02",{"date":94,"type":36},{"date":164,"type":36},"2025-07-07",{"date":166,"type":21},"2026-03-23",{"name":42,"class":43},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":44},"100627545","lrfn5-and-olfm4-in-methamphetamine-induced-psychosis-100627545","NCT07450027","LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis","Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study","49 Years",{"count":176,"type":21},120,"This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.",[113,179],"Methamphetamine-induced Psychosis",[181,182,87,183,184,185],"LRFN5","OLFM4","Psychotic Disorder","Methamphetamine Psychosis","Psychostimulants","2026-02-27",{"date":94,"type":36},{"date":189,"type":36},"2025-09-01",{"date":191,"type":21},"2026-04-01",{"name":42,"class":43},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100627386","lrfn5-and-olfm4-in-schizoaffective-disorder-100627386","NCT07447960","LRFN5 and OLFM4 in Schizoaffective Disorder","LRFN5 and OLFM4 Levels in Schizoaffective Disorder: A Cross-Sectional Case-Control Study","1. For Schizoaffective Disorder (SAD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of SAD according to DSM-5-TR\n   * Acute manic episode\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Schizoaffective Disorder (SAD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n\n   • Severe neurological disorders\n\n   • Immunological or systemic illness\n\n   • Primary psychiatric disorders other than SAD\n   * Alcohol\u002Fdrug\u002Fsubstance use\n2. For Healthy Control Group:\n\n   \\*Inclusion Criteria:\n\n   • No psychiatric diagnosis\n\n   • No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years and \\\u003C 65 years\n   * Provided informed consent\n\nFor Healthy Control Group:\n\n\\*Exclusion Criteria:\n\n* Hypertension\n* Diabetes mellitus\n* Chronic kidney disease\n* Rheumatoid arthritis\n* Systemic lupus erythematosus\n* Cardiac illness\n* Severe neurological disorders\n* Immunological or systemic illness\n* Having psychiatric disorders\n* Alcohol\u002Fdrug\u002Fsubstance use",{"count":176,"type":21},"Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.",[203],"Schizoaffective Disorder",[203,181,182,205,206],"Biomarkers","Neuroinflammation","2026-02-26",{"date":94,"type":36},{"date":161,"type":21},{"date":211,"type":21},"2026-05-29",{"name":42,"class":43},""]